American Association for Cancer Research
Browse
23266066cir140090-sup-cir-14-0090figleg.pdf (199.62 kB)

Supplementary Figure Legends from Mechanisms That Can Promote Peripheral B-cell Lymphoma in ATM-Deficient Mice

Download (199.62 kB)
journal contribution
posted on 2023-04-03, 23:05 authored by Suprawee Tepsuporn, Jiazhi Hu, Monica Gostissa, Frederick W. Alt

PDF file - 199K

History

ARTICLE ABSTRACT

The Ataxia Telangiectasia–mutated (ATM) kinase senses DNA double-strand breaks (DSB) and facilitates their repair. In humans, ATM deficiency predisposes to B- and T-cell lymphomas, but in mice it leads only to thymic lymphomas. We tested the hypothesis that increased DSB frequency at a cellular oncogene could promote B-cell lymphoma by generating ATM-deficient mice with a V(D)J recombination target (DJβ cassette) within c-myc intron 1 (“DA” mice). We also generated ATM-deficient mice carrying an Eμ-Bcl-2 transgene (AB mice) to test whether enhanced cellular survival could promote B-cell lymphomas. About 30% of DA or AB mice and nearly 100% of mice harboring the combined genotypes (DAB mice) developed mature B-cell lymphomas. In all genotypes, B-cell tumors harbored oncogenic c-myc amplification generated by breakage–fusion–bridge (BFB) from dicentric chromosomes formed through fusion of IgH V(D)J recombination–associated DSBs on chromosome 12 to sequences downstream of c-myc on chromosome 15. AB tumors demonstrate that B lineage cells harboring spontaneous DSBs leading to IgH/c-myc dicentrics are blocked from progressing to B-cell lymphomas by cellular apoptotic responses. DA and DAB tumor translocations were strictly linked to the cassette, but occurred downstream, frequently in a 6-kb region adjacent to c-myc that harbors multiple cryptic V(D)J recombination targets, suggesting that bona fide V(D)J target sequences may activate linked cryptic targets. Our findings indicate that ATM deficiency allows IgH V(D)J recombination DSBs in developing B cells to generate dicentric translocations that, via BFB cycles, lead to c-myc–activating oncogenic translocations and amplifications in mature B cells. Cancer Immunol Res; 2(9); 857–66. ©2014 AACR.